Amarin Corp. PLC (NASDAQ:AMRN)’s share price fell 1.4% on Wednesday . The stock traded as low as $2.13 and last traded at $2.14, with a volume of 628,301 shares changing hands. The stock had previously closed at $2.17.

Several research firms have recently weighed in on AMRN. Jefferies Group restated a “buy” rating on shares of Amarin Corp. PLC in a research report on Tuesday, May 31st. Zacks Investment Research upgraded shares of Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Amarin Corp. PLC in a research report on Monday, May 9th.

The stock has a 50 day moving average of $2.05 and a 200 day moving average of $1.71. The company’s market cap is $394.70 million.

Amarin Corp. PLC (NASDAQ:AMRN) last released its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by $0.03. During the same quarter in the previous year, the business earned ($0.16) earnings per share. The company earned $25.30 million during the quarter, compared to analyst estimates of $26.77 million. The firm’s quarterly revenue was up 60.4% compared to the same quarter last year. Analysts expect that Amarin Corp. PLC will post ($0.49) EPS for the current year.

Other hedge funds have recently made changes to their positions in the company. OppenheimerFunds Inc. raised its stake in shares of Amarin Corp. PLC by 0.5% in the fourth quarter. OppenheimerFunds Inc. now owns 5,323,360 shares of the biopharmaceutical company’s stock worth $10,061,000 after buying an additional 27,090 shares during the last quarter. Tamarack Advisers LP purchased a new stake in shares of Amarin Corp. PLC during the fourth quarter worth approximately $10,395,000. Finally, Oracle Investment Management Inc. raised its stake in shares of Amarin Corp. PLC by 9.4% in the fourth quarter. Oracle Investment Management Inc. now owns 6,645,793 shares of the biopharmaceutical company’s stock worth $12,561,000 after buying an additional 568,915 shares during the last quarter.

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.